Research Protocol

 
News Articles for Research Protocol top ^
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval Safety and Efficacy Data from Over 30 CLL Patients from the On-going Phase 2 Trial of the Combination of TG-1101 plus ibrutinib Anticipated to be Presented at ASH 2014 NEW YORK, Sept.
Sign-up for TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia investment picks
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel ® bacterial vaginosis (BV) product for the prevention of recurrent BV.
Sign-up for FDA Grants Special Protocol Assessment (SPA) Agreement for Starpharma Phase 3 Recurrent BV Trial investment picks
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Pfizer Inc., the company responsible for ongoing clinical development for rivipansel (GMI-1070), has reached agreement with the U.S. Food & Drug Administration (FDA) under a special protocol assessment (SPA) for a Phase 3 trial for rivipansel.
Sign-up for GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070) investment picks
http://media.marketwire.com/attachments/201103/23230_Advant.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1125600&ProfileId=051205&sourceType=1 TOKYO, JAPAN --
Sign-up for Advantest Launches 1.6-Gbps Digital Module Enabling Protocol-Aware Testing With Powerful EDA-Link (FTA-Elink) investment picks
Signs Business Collaboration in South Korea with Wonik Corporation Second Quarter 2014 Conference Call Friday August 15th at 9:00 am BRIDGEWATER, N.J. , Aug.
Sign-up for FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol investment picks
2014/6/23
BRIDGEWATER, N.J. , June 23, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the progress of on-going discussions with the U.S. Food and Drug Administration for a planned pivotal Phase 3 randomized controlled trial ("RCT") for Neutrolin® for use in hemodialysis patients with a central venous catheter.
Sign-up for CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA investment picks
Hyde Marine, Inc., announces today it will begin using a new ballast water test system, B-box, recently made available from the Royal Netherlands Institute for Sea Research (NIOZ) to help ballast water treatment (BWT) technology companies conduct accurate analysis regarding the concentrations of chemicals or organisms present in ballast water.
Sign-up for Hyde Marine to Provide B-box Ballast Water Treatment Service, NIOZ Testing Protocol to Help Validate System Performance investment picks
- Amended Design Expedites Phase 1/2 Trial of Heat's Immuno-Therapy Bladder Cancer Product Candidate – - Provides Accelerated Timeline to Phase 2 Results - DURHAM, N.C., Aug.
Sign-up for Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Protocol
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Proposals  |  Next: Research Providers